Imlifidase (Idefirix®). HTA ID 23041

Assessment Status Full HTA submission received from Applicant
HTA ID 23041
Drug Imlifidase
Brand Idefirix®
Indication For desensitisation treatment of highly sensitised adult kidney transplant patients with positive crossmatch against an available deceased donor. The use of imlifidase should be reserved for patients unlikely to be transplanted under the available kidney allocation system including prioritisation programmes for highly sensitised patients.
Assessment Process
Rapid review commissioned 19/07/2023
Rapid review completed 01/08/2023
Rapid review outcome A full HTA is recommended to assess the clinical effectiveness and cost effectiveness of imlifidase compared with the current standard of care.
Full pharmacoeconomic assessment commissioned by HSE 30/08/2023
Pre-submission consultation with Applicant 21/11/2023
Full submission received from Applicant 22/04/2024